Ask AI
CD38 Quadruplet Therapy for NDMM

CE / CME

Conference to Clinic: Integrating CD38-Based Quadruplet Therapy Into Care of Transplant-Ineligible and Transplant-Eligible NDMM

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: July 29, 2025

Expiration: January 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

An 80-yr-old man presents with progressive fatigue, weight loss, and new-onset back pain. Laboratory evaluation reveals hemoglobin 9.5 g/dL, serum creatinine 1.3 mg/dL, and serum M-protein 3.8 g/dL. Bone marrow biopsy confirms 50% clonal plasma cells and he is diagnosed with multiple myeloma. He has controlled hypertension, his ECOG PS is 1, and he is considered transplant ineligible. Which of the following treatment regimens would be most appropriate?

2.

In your practice, which of the following infections do you routinely provide infection prophylaxis in patients receiving anti-CD38 antibodies?

3.

How confident are you to implement strategies supporting equitable access to novel therapies and supportive care in Black and underserved patients with multiple myeloma?